📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Determining the prognostic significance of IKKa in prostate cancer. (2020)

First Author: Montes M

Attributed to: First-in-class Selective IKKalpha Inhibitors for the Treatment of Castrate Resistant Prostate Cancer (CRPC) and Pancreatic Cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/pros.24045

PubMed Identifier: 33258506

Publication URI: http://europepmc.org/abstract/MED/33258506

Type: Journal Article/Review

Volume: 80

Parent Publication: The Prostate

Issue: 14

ISSN: 0270-4137